A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002059
- Lead Sponsor
- Newport Pharmaceuticals International
- Brief Summary
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to:
* Comparison of total helper and suppressor T-cell number between the groups.
* Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups.
* Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Newport Pharmaceuticals International Inc
🇺🇸Laguna Hills, California, United States